NeoPrediX - Investor Relations

INVESTOR RELATIONS

Kontaktieren Sie uns jederzeit gerne: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

Vorhersage Plattform um klinische Entscheidungen zu Unterstützen

Warum in NeoPrediX investieren?

Software-as-a-Service
Digital Health
bahnbrechende Vorhersagesoftware
weltweites Marktpotenzial
Engagiertes Team von Wissenschafts- und Marktexperten

Investor Kalender

NeoPrediX nimmt an folgenden Investorenkonferenzen teil:

Keine Termine

INVESTOREN MEDIEN ZENTRUM:

Intro NeoPrediX B.1

About us

Our employees about NeoPrediX

NeoPrediX @LSI USA `22

Pressemeldungen

Multi-Center Observational Study

Clinical Decision Support Company NeoPrediX AG Completes Prospective Multi-Center Observational Study

Basel, Switzerland, Regensburg, Germany, and Ft. Lauderdale, FL, USA, May 25, 2022 – NeoPrediX AG, a privately held maternal and neonatal clinical decision support company focused on the development and commercialization of intelligent algorithms to predict dynamic progression of disease parameters during the first 1,000 days of life, announced at a poster presentation during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine held in Aachen, Germany, that a prospective multi-center observational study was formally completed.

NeoPrediX PRESENT AT BIOTECH SHOWCASE™ 2022

Breakthrough Prediction Software Platform of NeoPrediX shown at BIOTECH SHOWCASE

Regensburg, Germany. 22nd of December 2021 – NeoPrediX today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation.

Start-up company opens first US office

NeoPrediX starts marketing its prediction software platform in USA

November 15, 2021 - With the establishment of NeoPrediX USA in Fort Lauderdale (Florida) the German/Swiss NeoPredix AG starts its US business and pushes its internationalization strategy. The start-up company develops prediction software for hospitals and neonatal units based on scientific and clinical data as well as science-based algorithms.

Wer ist NeoPrediX?

NeoPrediX AG is a Swiss company located in Basel with subsidiaries in Regensburg, Germany and Ft. Lauderdale, Florida, USA.

Kontakt

Sie möchten uns näher kennenlernen?
Schreiben Sie uns gerne Ihre Fragen oder Wünsche!
Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!